264MH, Scientist, Cancer Immunotherapy

Job Code 264MH


Fate Therapeutics is seeking a highly motivated Immunologist with expertise in cancer T cell biology to join a multidisciplinary team dedicated to the discovery of novel cellular therapies for the treatment of solid tumors. The candidate must have in-depth knowledge of T cell biology in the context of cancer, auto-immunity, and/or infectious disease, in addition to extensive experience with in vitro and in vivo functional immune cell assays. Experience with in vivo cell-derived xenograft, patient-derived xenograft, and/or syngeneic tumor models is highly desired. This position will be a key member of our cancer immunotherapy team and will assist in performing and analyzing studies involving in vitro, in vivo, and ex vivo testing of Fate Therapeutics’ novel cellular therapy products. This is a full-time, bench-level position reporting to a Senior Scientist in Cancer Immunotherapy located at the Company’s corporate headquarters in San Diego, California.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 264MH.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.